FIELD: chemistry.
SUBSTANCE: present invention relates to immunology. Disclosed are monoclonal antibodies which bind to the extracellular domain of receptor tyrosine kinase AXL and which at least partially inhibit AXL activity, as well as antigen-binding fragments. Also provided is an isolated nucleic acid molecule, a host cell and a method of producing a monoclonal antibody and an antigen-binding fragment thereof, as well as use of the monoclonal antibody or antigen-binding fragment thereof to produce a drug, pharmaceutical compositions, a method of diagnosing and a method of preventing or treating a condition associated with expression, overexpression and/or hyperactivity of AXL.
EFFECT: invention can be used in therapy and diagnosis of diseases associated with AXL.
23 cl, 20 dwg, 24 ex, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| HUMANISED ANTI-AXL ANTIBODIES | 2010 |
|
RU2571224C2 |
| MONOCLONAL ANTIBODIES CAPABLE OF BINDING WITH AXL PROTEIN AND THEIR APPLICATION | 2008 |
|
RU2559530C2 |
| ANTIGEN-BINDING PROTEIN AND ITS APPLICATION AS A PRODUCT FOR ADDRESS DELIVERY IN TREATMENT OF CANCER | 2012 |
|
RU2650771C1 |
| AXL SIGNALLING INHIBITION IN ANTIMETASTATIC THERAPY | 2011 |
|
RU2556822C2 |
| ANTIGEN BINDING PROTEIN AND USE THEREOF AS ADDRESSING PRODUCT FOR TREATMENT OF CANCER | 2012 |
|
RU2659094C2 |
| BINDING PROTEINS SPECIFIC TO INSULIN-LIKE GROWTH FACTORS, AND USING THEM | 2013 |
|
RU2549703C2 |
| ANTIBODIES AGAINST AXL AND THEIR APPLICATION | 2011 |
|
RU2577986C2 |
| ANTI-CXCR4 ANTIBODIES AND USING THEM FOR TREATING CANCER | 2009 |
|
RU2573897C2 |
| HUMANISED ANTI-CXCR4 ANTIBODIES FOR TREATING CANCER | 2011 |
|
RU2595394C2 |
| ANTIBODIES TO PD-1 AND METHODS OF THEIR APPLICATION | 2015 |
|
RU2701797C2 |
